Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 2/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RPA1 | P27694 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728535 | 0.83 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GKDM4EALDH1A1GAA | |
| SCHEMBL21996935 | 0.82 | APOBEC3A (0.41) | APOBEC3AAPOBEC3GKDM4EP2RY14 | |
| SCHEMBL15287379 | 0.76 | APOBEC3A (0.53) | APOBEC3AAPOBEC3GKDM4EALDH1A1GAA | |
| SCHEMBL22672595 | 0.76 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GKDM4EALDH1A1GAA | |
| SCHEMBL23728605 | 0.75 | APOBEC3A (0.51) | APOBEC3AAPOBEC3GKDM4EALDH1A1GAA | |
| SCHEMBL17141136 | 0.73 | KDM4E (0.43) | APOBEC3AAPOBEC3GKDM4EALDH1A1GAA | |
| SCHEMBL5133266 | 0.73 | APOBEC3A (0.49) | APOBEC3AAPOBEC3GKDM4EALDH1A1HSD17B10 | |
| SCHEMBL21997579 | 0.72 | L3MBTL3 (0.40) | APOBEC3AAPOBEC3GSMPD3L3MBTL1 | |
| SCHEMBL25338105 | 0.71 | APOBEC3A (0.47) | APOBEC3AAPOBEC3GSMPD3KDM4EALDH1A1 | |
| SCHEMBL22777747 | 0.71 | ALDH1A1 (0.58) | APOBEC3AAPOBEC3GKDM4EALDH1A1RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | APOBEC3A 219/4885APOBEC3G 151/4885SMPD3 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.